Method of enhancing an immune response
A method of enhancing an immune response to an antigen is provided. The method involves augmenting the level of a TAP molecule in a target cell bearing the antigen. Preferably, the TAP molecules enhanced by administering a nucleic acid sequence encoding a TAP-1 and/or TAP-2 molecule. The method is useful in treating infectious diseases and cancer.
1. A method of enhancing a cytotoxic T-lymphocyte response in an animal to tumor cells which express low to non-detectable levels of peptide/MHC class 1 complexes on the cell surface, comprising:
administering ex vivo a nucleic acid sequence encoding a TAP-1 molecule into said tumor cells;
irradiating said tumor cells; and
introducing said tumor cells containing TAP-1 nucleic acid sequences into said animal.
2. The method according to claim 1 , wherein the animal is also subjected to surgery, radiation, chemotherapy, immunotherapy or photodynamic therapy.
3. The method according to claim 1 , wherein said introducing step is performed intraperitoneally, intratumorally, subcutaneously, intravenously, orally, mucosally, submucosally or intradermally.
4. The method according to claim 1 , wherein said nucleic acid sequence encodes both the TAP-1 molecule and a TAP-2 molecule.
5. A method of enhancing a cytotoxic T-lymphocyte response in an animal to tumor cells which express low to non-detectable levels of peptide/MHC class 1 complexes on the cell surface comprising:
introducing into the animal, at a location into or near the tumor cell a viral vector encoding a TAP-1 molecule in a manner which causes uptake by said tumor cells of said viral vector, resulting in the expression of TAP-1 in said tumor cells.
6. The method according to claim 5 wherein the viral vector is selected from the group consisting of vaccinia based vectors, adenovirus based vectors, lenti virus based vectors and HSV based vectors.
7. The method according to claim 5 , wherein said viral vector encodes both the TAP-1 molecule and a TAP-2 molecule.